Q-omics provides the consensus-scored CFAP298-TCP10L profile across patient tissues and cancer cell-line models. CFAP298-TCP10L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CFAP298-TCP10L is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, CFAP298-TCP10L RNA expression shows 13,504 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUAD, KICH, and HNSC as cancer lineages where CFAP298-TCP10L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFAP298-TCP10L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFAP298-TCP10L survival associations across molecular data types. CFAP298-TCP10L RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFAP298-TCP10L RNA expression–survival associations across cancer types. High CFAP298-TCP10L expression shows unfavorable associations in LUAD, COAD and UCEC, but favorable associations in ACC, THCA and MESO. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CFAP298-TCP10L RNA expression.
This table summarizes CFAP298-TCP10L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CFAP298-TCP10L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFAP298-TCP10L shows lower tumor expression in KICH, COAD and THCA and higher tumor expression in LIHC, BRCA and CHOL. The KICH box plot shows higher CFAP298-TCP10L RNA expression in normal versus tumor tissue (log2 FC = −0.721, t-test p < 0.001).
This table shows molecular features associated with CFAP298-TCP10L in patient tissues and cancer cell lines. In patient samples, CFAP298-TCP10L shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, CFAP298-TCP10L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma.
